Table 3 Treatment decision, duration, and outcome in both HCV patients post chemotherapy (cases) and HCV patients without cancer (controls)
Groups of HCV patients | Total N (%) 171 | p-value | |||
|---|---|---|---|---|---|
Post chemotherapy N (%) 83 | Without cancer N (%) 88 | ||||
Treatment decision | IFN/SOF/RBV | 12 (14.5%) | 5 (5.7%) | 17 (9.9%) | |
PAR/OMP/RBV | 1 (1.2%) | 1 (1.1%) | 2 (1.2%) | ||
SOF/DAC | 18 (21.7%) | 44 (50%) | 62 (36.3%) | ||
SOF/DAC/RBV | 16 (19.3%) | 20 (22.7%) | 36 (21.1%) | ||
SOF/PAR/OMP/RBV | 1 (1.2%) | 0 (0%) | 1 (0.6%) | ||
SOF/RBV | 23 (27.7%) | 18 (20.5%) | 41 (24%) | ||
SOF/SIM | 12 (14.5%) | 0 (0%) | 12 (7%) | ||
Treatment duration | 12 weeks | 55 (66.3%) | 58 (65.9%) | 113 (66.1%) | 0.961 |
24 weeks | 28 (33.7%) | 30 (34.1 %) | 58 (33.9%) | ||
Treatment outcome | SVR | 83 (100%) | 86 (97.7%) | 169 (98.9%) | 0.497 |
Non SVR | 0 (0%) | 2 (2.3%) | 2 (1.2%) | ||
SVR | 83 (100%) | 86 (97.7%) | 169 (98.9%) | 0.385 | |
Relapser | 0 (0%) | 1 (1.1%) | 1 (0.6%) | ||
DC | 0 (0%) | 1 (1.1%) | 1 (0.6%) | ||